{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"18.4","value":"6.5"},{"groupId":"OG001","lowerLimit":"5.9","upperLimit":"19.1","value":"6.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"TTR was defined as the time from the date of first dose to first radiographic evidence of response (CR or PR) per RECIST v1.1 by derived investigator assessment. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR: \\>= 30% decrease under baseline of the sum of diameters of all target measurable lesions.","dispersionType":"Full Range","groups":[{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 180 mg/m\\^2 as IV infusion for 90 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"Cohort 3: Arm D [EC + FOLFIRI]"},{"description":"Participants received fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 180 mg/m\\^2 as IV infusion for 90 minutes Q2W with or without bevacizumab. Bevacizumab was optional and it was given per prescribing instructions of treating physician. Participants received treatment in 28-day cycles.","id":"OG001","title":"Cohort 3: Arm E [FOLFIRI With or Without Bevacizumab]"}],"paramType":"MEDIAN","populationDescription":"The FAS for Cohort 3 included all participants who were randomized in the Cohort 3 portion of the study, respectively. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure with a confirmed objective response by derived investigator assessment.","reportingStatus":"POSTED","timeFrame":"From date of first dose to CR or PR (maximum up to 14.1 months [61.29 weeks])","title":"Cohort 3: TTR by Derived Investigator Assessment - FAS","type":"SECONDARY","unitOfMeasure":"Weeks"}